Clinical cure · bacterial folliculitis and boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse events leading to withdrawal of treatment · bacterial folliculitis and boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · bacterial folliculitis and boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of folliculitis or boil following completion of treatment · bacterial folliculitis and boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events not leading to withdrawal of treatment · bacterial folliculitis and boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with medium‐dose UVA‐1 phototherapy (50 J/cm²) (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Narrowband UVB phototherapy may leads to lower primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Adverse events associated with treatment · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
Medium‐dose UVA‐1 phototherapy (50 J/cm²) showed no clear difference in primary outcome: Adverse effects compared with low‐dose UVA‐1 phototherapy (20 J/cm²) (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (skin softening) · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised…
The review found no eligible studies for this question.
1 finding from 1 review
Physician‐assessed changes in clinical signs · atopic eczema
1 finding from 1 review
Withdrawals due to adverse events · atopic eczema
1 finding from 1 review
Physician‐assessed changes in clinical signs · atopic eczema
1 finding from 1 review